For instance, genetic alterations in oncogenic drivers, such as the Kirsten rat sarcoma (KRAS), v-raf murine sarcoma viral oncogene homolog B (BRAF), and epidermal growth factor receptor (EGFR) genes, are commonly found in patients with NSCLC and can affect their response to treatments (Chevallier et al., 2021). This evidence concerns the gene BRAF and non-small cell lung carcinoma.